We herein report on a retrospective series of 11 patients with locally advanced/metastatic EMC, molecularly confirmed by the presence of NR4A3 rearrangement, treated with anthracycline-based chemotherapy at our institution and within the Italian Rare Cancer Network. Here, NR4A3 is linked to extraskeletal myxoid chondrosarcoma.